To our investors -

It looks like my recent post and update did not reach many of our investors. So that our gratitude is conveyed, allow me to repeat much of what I said and to give you more information. To all of each and every one of our initial investors, we want to extend our sincere appreciation for your vote of confidence. In the 3 weeks we have been on wefunder, we have 160 investors! When we decided on a crowd funding effort, we didn't know exactly what to expect. And certainly we did not expect to have over 160 investors in the first 3 weeks. We knew we had a technology that had to be advanced and we believed that once it was revealed to the masses, people would respond. That has been the case and we are most grateful for it.

Looking at the large number of investors that have joined our effort in a rather short time period, it is apparent to us that our potential has resonated with wefunders. We believe the reason is that people will respond favorably to help those in need when they see a situation where millions have absolutely no treatment for a devastating illness like HIV and where the minority who are being treated have less than an optimum therapy. We look forward to moving ahead successfully and sharing our success with each of our investors.

As an update, we have this week been contacted by a large Indian pharmaceutical company (whose focus is vaccines) that it is interested in a meeting with us to discuss the second side of our technology – namely an anti-HIV vaccine. To explain, there are 2 sides to this technology – the first is our current focus, namely a therapy for those who have the virus. The second is a vaccine that would prevent a person from ever becoming infected. Our technology opens the doors to both. Our hopeful collaboration with this large pharmaceutical company relates to this second focus, namely a vaccine against HIV. Additionally, we are in contact with a large US pharmaceutical company who has a portfolio of therapies in our focus area. We expect to be dialoguing with them regarding a joint development program.

Also, our NIH grant application is pending and Congress just this week increased the NIH budget for the next 5 months by an additional $2 Billion to support medical research. This is a benefit to all grant applicants - including us. Our application is currently pending and awards will be named later this year.

Thanks again for being an investor and joining us in our mission to positively improve the lives of millions. And please share our technology with those you know.

Best regards,

Charles Cotropia

CEO, BioClonetics Immunotherapeutics, Inc.